Sandra Zaky, MD
Radiation Oncology · Stanford, CANPI 1487830741
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.7% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Siemens Medical Solutions USA, Inc. at 24.3% of the total. Reporting peaked in 2023 at $228 and has fallen 79.4% since, to $47 in 2025. That places this record below the midpoint for radiation oncology clinicians in CA, where the typical reported total is $477.
Across 17 payments — averaging $30.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Siemens Medical Solutions USA, Inc.$127
- Boston Scientific$60
- Amgen$51
- Springworks Therapeutics, Inc.$47
- EMD Serono, Inc.$44
- Bioprotect Medical, Inc.$42
- plus $154 from 6 others
What the payments were for
- Food & beverage$48292%
- Education$448%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Siemens Medical Solutions USA, Inc. | 3 | $127 |
| Boston Scientific | 2 | $60 |
| Amgen | 2 | $51 |
| Springworks Therapeutics, Inc. | 1 | $47 |
| EMD Serono, Inc. | 1 | $44 |
| Bioprotect Medical, Inc. | 1 | $42 |
| Novocure Inc. | 2 | $35 |
| Merck | 1 | $31 |
| Teleflex LLC | 1 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Monteris Medical Corporation | 1 | $19 |
| Varian Medical Systems, Inc. | 1 | $16 |
How this compares
$525 in reported general payments places this provider in the 50th percentile of 627 radiation oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 49 | $838 |
| Oxybutynin Chloride ErOxybutynin Chloride | 21 | $408 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $405 |
| Terazosin Hcl | 20 | $300 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Stanford
- Maximilian DiehnStanford$73K
- Yushen QianStanford$47K
- Anusha KalbasiStanford$37K
- Rishabh ChaudhariStanford$35K
- Quynh-Thu leStanford$23K
- Scott SoltysStanford$19K
- Noah Kastelowitz-LiebermanStanford$17K
- Billy LooStanford$11K
- Rakesh PatelLos Gatos$1.3M
- Amir LavafPalm Springs$411K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.